nodes	percent_of_prediction	percent_of_DWPC	metapath
Adenosine—Respiratory arrest—Vandetanib—thyroid cancer	0.0275	0.0469	CcSEcCtD
Adenosine—SLC28A3—trachea—thyroid cancer	0.0244	0.104	CbGeAlD
Adenosine—Micturition urgency—Vandetanib—thyroid cancer	0.0213	0.0364	CcSEcCtD
Adenosine—ADORA2B—trachea—thyroid cancer	0.0174	0.0744	CbGeAlD
Adenosine—Torsade de pointes—Vandetanib—thyroid cancer	0.0172	0.0294	CcSEcCtD
Adenosine—ADK—saliva-secreting gland—thyroid cancer	0.0169	0.0721	CbGeAlD
Adenosine—DPP4—saliva-secreting gland—thyroid cancer	0.0163	0.0699	CbGeAlD
Adenosine—Ventricular arrhythmia—Vandetanib—thyroid cancer	0.0163	0.0279	CcSEcCtD
Adenosine—ADORA1—saliva-secreting gland—thyroid cancer	0.0162	0.0693	CbGeAlD
Adenosine—Electrocardiogram ST segment depression—Epirubicin—thyroid cancer	0.0133	0.0227	CcSEcCtD
Adenosine—ADK—trachea—thyroid cancer	0.013	0.0556	CbGeAlD
Adenosine—ADA—thyroid gland—thyroid cancer	0.0126	0.0539	CbGeAlD
Adenosine—Respiratory failure—Vandetanib—thyroid cancer	0.0123	0.021	CcSEcCtD
Adenosine—Electrocardiogram ST segment depression—Doxorubicin—thyroid cancer	0.0123	0.021	CcSEcCtD
Adenosine—ADORA2B—head—thyroid cancer	0.0122	0.0522	CbGeAlD
Adenosine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TCF7L1—thyroid cancer	0.0115	0.0652	CbGpPWpGaD
Adenosine—ADA—head—thyroid cancer	0.0112	0.0478	CbGeAlD
Adenosine—ADK—thyroid gland—thyroid cancer	0.0103	0.044	CbGeAlD
Adenosine—ADORA2A—head—thyroid cancer	0.0102	0.0435	CbGeAlD
Adenosine—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0101	0.0173	CcSEcCtD
Adenosine—DPP4—thyroid gland—thyroid cancer	0.00997	0.0427	CbGeAlD
Adenosine—ADORA1—thyroid gland—thyroid cancer	0.00989	0.0423	CbGeAlD
Adenosine—Atrial fibrillation—Vandetanib—thyroid cancer	0.00925	0.0158	CcSEcCtD
Adenosine—ADK—head—thyroid cancer	0.00912	0.039	CbGeAlD
Adenosine—Cardiac failure—Vandetanib—thyroid cancer	0.00898	0.0154	CcSEcCtD
Adenosine—DPP4—head—thyroid cancer	0.00885	0.0378	CbGeAlD
Adenosine—ADORA1—head—thyroid cancer	0.00877	0.0375	CbGeAlD
Adenosine—Cardiac arrest—Vandetanib—thyroid cancer	0.00834	0.0142	CcSEcCtD
Adenosine—Blood pressure increased—Sorafenib—thyroid cancer	0.00815	0.0139	CcSEcCtD
Adenosine—Supraventricular extrasystoles—Epirubicin—thyroid cancer	0.00808	0.0138	CcSEcCtD
Adenosine—ADA—lymph node—thyroid cancer	0.00782	0.0335	CbGeAlD
Adenosine—Supraventricular extrasystoles—Doxorubicin—thyroid cancer	0.00748	0.0128	CcSEcCtD
Adenosine—Sinus tachycardia—Epirubicin—thyroid cancer	0.00747	0.0128	CcSEcCtD
Adenosine—Bronchospasm—Vandetanib—thyroid cancer	0.00745	0.0127	CcSEcCtD
Adenosine—ADORA2B—G alpha (s) signalling events—CALCB—thyroid cancer	0.00732	0.0415	CbGpPWpGaD
Adenosine—Pollakiuria—Vandetanib—thyroid cancer	0.007	0.012	CcSEcCtD
Adenosine—Sinus tachycardia—Doxorubicin—thyroid cancer	0.00692	0.0118	CcSEcCtD
Adenosine—ADK—lymph node—thyroid cancer	0.00639	0.0273	CbGeAlD
Adenosine—DPP4—lymph node—thyroid cancer	0.00619	0.0265	CbGeAlD
Adenosine—Bradycardia—Vandetanib—thyroid cancer	0.00617	0.0106	CcSEcCtD
Adenosine—ADORA1—lymph node—thyroid cancer	0.00614	0.0263	CbGeAlD
Adenosine—Cardiac failure—Sorafenib—thyroid cancer	0.00606	0.0104	CcSEcCtD
Adenosine—Cardiac disorder—Vandetanib—thyroid cancer	0.00563	0.00962	CcSEcCtD
Adenosine—Mood swings—Sorafenib—thyroid cancer	0.0056	0.00958	CcSEcCtD
Adenosine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00547	0.00934	CcSEcCtD
Adenosine—Arrhythmia—Vandetanib—thyroid cancer	0.00542	0.00926	CcSEcCtD
Adenosine—Dysgeusia—Vandetanib—thyroid cancer	0.00517	0.00884	CcSEcCtD
Adenosine—Vision blurred—Vandetanib—thyroid cancer	0.00498	0.0085	CcSEcCtD
Adenosine—Adenosine triphosphate—AKT1—thyroid cancer	0.00496	1	CrCbGaD
Adenosine—Tremor—Vandetanib—thyroid cancer	0.00495	0.00845	CcSEcCtD
Adenosine—ADORA2A—HIF-2-alpha transcription factor network—EPO—thyroid cancer	0.00491	0.0279	CbGpPWpGaD
Adenosine—Abdominal discomfort—Sorafenib—thyroid cancer	0.0049	0.00838	CcSEcCtD
Adenosine—ADORA2A—G alpha (s) signalling events—CALCB—thyroid cancer	0.0048	0.0272	CbGpPWpGaD
Adenosine—Loss of consciousness—Vandetanib—thyroid cancer	0.00464	0.00793	CcSEcCtD
Adenosine—Cough—Vandetanib—thyroid cancer	0.00461	0.00787	CcSEcCtD
Adenosine—ADA—Validated transcriptional targets of deltaNp63 isoforms—NRG1—thyroid cancer	0.00458	0.026	CbGpPWpGaD
Adenosine—Convulsion—Vandetanib—thyroid cancer	0.00457	0.00782	CcSEcCtD
Adenosine—Hypertension—Vandetanib—thyroid cancer	0.00456	0.00779	CcSEcCtD
Adenosine—Chest pain—Vandetanib—thyroid cancer	0.00449	0.00768	CcSEcCtD
Adenosine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00449	0.00768	CcSEcCtD
Adenosine—Anxiety—Vandetanib—thyroid cancer	0.00448	0.00766	CcSEcCtD
Adenosine—Myocardial infarction—Sorafenib—thyroid cancer	0.00447	0.00764	CcSEcCtD
Adenosine—Dry mouth—Vandetanib—thyroid cancer	0.0044	0.00751	CcSEcCtD
Adenosine—Hyperventilation—Epirubicin—thyroid cancer	0.00437	0.00748	CcSEcCtD
Adenosine—Burning sensation—Epirubicin—thyroid cancer	0.00433	0.00741	CcSEcCtD
Adenosine—ADA—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00408	0.0232	CbGpPWpGaD
Adenosine—Ventricular arrhythmia—Epirubicin—thyroid cancer	0.00407	0.00695	CcSEcCtD
Adenosine—Hyperventilation—Doxorubicin—thyroid cancer	0.00405	0.00692	CcSEcCtD
Adenosine—Burning sensation—Doxorubicin—thyroid cancer	0.00401	0.00685	CcSEcCtD
Adenosine—Scotoma—Epirubicin—thyroid cancer	0.00396	0.00678	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00393	0.00671	CcSEcCtD
Adenosine—Paraesthesia—Vandetanib—thyroid cancer	0.00387	0.00661	CcSEcCtD
Adenosine—Dyspnoea—Vandetanib—thyroid cancer	0.00384	0.00657	CcSEcCtD
Adenosine—Tinnitus—Sorafenib—thyroid cancer	0.00381	0.00652	CcSEcCtD
Adenosine—Cardiac disorder—Sorafenib—thyroid cancer	0.0038	0.00649	CcSEcCtD
Adenosine—Flushing—Sorafenib—thyroid cancer	0.0038	0.00649	CcSEcCtD
Adenosine—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.00376	0.00643	CcSEcCtD
Adenosine—ADA—p73 transcription factor network—CDK1—thyroid cancer	0.00376	0.0213	CbGpPWpGaD
Adenosine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00369	0.0063	CcSEcCtD
Adenosine—Pain—Vandetanib—thyroid cancer	0.00368	0.0063	CcSEcCtD
Adenosine—Scotoma—Doxorubicin—thyroid cancer	0.00367	0.00627	CcSEcCtD
Adenosine—Arrhythmia—Sorafenib—thyroid cancer	0.00365	0.00625	CcSEcCtD
Adenosine—Dysgeusia—Sorafenib—thyroid cancer	0.00349	0.00596	CcSEcCtD
Adenosine—ADORA2B—G alpha (s) signalling events—TSHR—thyroid cancer	0.00339	0.0192	CbGpPWpGaD
Adenosine—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00333	0.0057	CcSEcCtD
Adenosine—Angioedema—Sorafenib—thyroid cancer	0.00325	0.00556	CcSEcCtD
Adenosine—Syncope—Sorafenib—thyroid cancer	0.00319	0.00546	CcSEcCtD
Adenosine—SLC28A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00315	0.0179	CbGpPWpGaD
Adenosine—SLC28A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00315	0.0179	CbGpPWpGaD
Adenosine—Loss of consciousness—Sorafenib—thyroid cancer	0.00313	0.00535	CcSEcCtD
Adenosine—Cough—Sorafenib—thyroid cancer	0.00311	0.00531	CcSEcCtD
Adenosine—Atrioventricular block—Epirubicin—thyroid cancer	0.0031	0.00531	CcSEcCtD
Adenosine—Asthenia—Vandetanib—thyroid cancer	0.00309	0.00528	CcSEcCtD
Adenosine—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00308	0.00527	CcSEcCtD
Adenosine—Hypertension—Sorafenib—thyroid cancer	0.00307	0.00526	CcSEcCtD
Adenosine—ADORA1—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00304	0.0172	CbGpPWpGaD
Adenosine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00301	0.00515	CcSEcCtD
Adenosine—Injection site reaction—Epirubicin—thyroid cancer	0.00299	0.00512	CcSEcCtD
Adenosine—Dry mouth—Sorafenib—thyroid cancer	0.00296	0.00507	CcSEcCtD
Adenosine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00291	0.00497	CcSEcCtD
Adenosine—Atrioventricular block—Doxorubicin—thyroid cancer	0.00287	0.00491	CcSEcCtD
Adenosine—Shock—Sorafenib—thyroid cancer	0.00286	0.00489	CcSEcCtD
Adenosine—Dizziness—Vandetanib—thyroid cancer	0.00285	0.00487	CcSEcCtD
Adenosine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00279	0.00476	CcSEcCtD
Adenosine—Injection site reaction—Doxorubicin—thyroid cancer	0.00277	0.00473	CcSEcCtD
Adenosine—Vomiting—Vandetanib—thyroid cancer	0.00274	0.00468	CcSEcCtD
Adenosine—Rash—Vandetanib—thyroid cancer	0.00272	0.00464	CcSEcCtD
Adenosine—Dermatitis—Vandetanib—thyroid cancer	0.00271	0.00464	CcSEcCtD
Adenosine—Headache—Vandetanib—thyroid cancer	0.0027	0.00461	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—CALCB—thyroid cancer	0.00266	0.0151	CbGpPWpGaD
Adenosine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00265	0.00453	CcSEcCtD
Adenosine—Dyspnoea—Sorafenib—thyroid cancer	0.00259	0.00443	CcSEcCtD
Adenosine—Nausea—Vandetanib—thyroid cancer	0.00256	0.00437	CcSEcCtD
Adenosine—ADORA2B—G alpha (s) signalling events—CALCA—thyroid cancer	0.00254	0.0144	CbGpPWpGaD
Adenosine—Pain—Sorafenib—thyroid cancer	0.00249	0.00425	CcSEcCtD
Adenosine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00236	0.0134	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00235	0.0133	CbGpPWpGaD
Adenosine—Urticaria—Sorafenib—thyroid cancer	0.00231	0.00395	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—CALCB—thyroid cancer	0.00226	0.0128	CbGpPWpGaD
Adenosine—Cardiac failure—Epirubicin—thyroid cancer	0.00224	0.00383	CcSEcCtD
Adenosine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00223	0.00381	CcSEcCtD
Adenosine—ADORA2A—G alpha (s) signalling events—TSHR—thyroid cancer	0.00222	0.0126	CbGpPWpGaD
Adenosine—Affect lability—Epirubicin—thyroid cancer	0.00215	0.00368	CcSEcCtD
Adenosine—Hypersensitivity—Sorafenib—thyroid cancer	0.00214	0.00366	CcSEcCtD
Adenosine—Asthenia—Sorafenib—thyroid cancer	0.00209	0.00356	CcSEcCtD
Adenosine—Cardiac arrest—Epirubicin—thyroid cancer	0.00208	0.00355	CcSEcCtD
Adenosine—Cardiac failure—Doxorubicin—thyroid cancer	0.00207	0.00354	CcSEcCtD
Adenosine—Mood swings—Epirubicin—thyroid cancer	0.00207	0.00354	CcSEcCtD
Adenosine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00206	0.00353	CcSEcCtD
Adenosine—ADK—Metabolism—MINPP1—thyroid cancer	0.00203	0.0115	CbGpPWpGaD
Adenosine—Affect lability—Doxorubicin—thyroid cancer	0.00199	0.0034	CcSEcCtD
Adenosine—Cardiac arrest—Doxorubicin—thyroid cancer	0.00192	0.00329	CcSEcCtD
Adenosine—Dizziness—Sorafenib—thyroid cancer	0.00192	0.00329	CcSEcCtD
Adenosine—Mood swings—Doxorubicin—thyroid cancer	0.00192	0.00327	CcSEcCtD
Adenosine—Vomiting—Sorafenib—thyroid cancer	0.00185	0.00316	CcSEcCtD
Adenosine—Rash—Sorafenib—thyroid cancer	0.00183	0.00313	CcSEcCtD
Adenosine—Dermatitis—Sorafenib—thyroid cancer	0.00183	0.00313	CcSEcCtD
Adenosine—Headache—Sorafenib—thyroid cancer	0.00182	0.00311	CcSEcCtD
Adenosine—Pollakiuria—Epirubicin—thyroid cancer	0.00174	0.00298	CcSEcCtD
Adenosine—ADORA2A—GPCR ligand binding—CALCB—thyroid cancer	0.00174	0.00989	CbGpPWpGaD
Adenosine—Nausea—Sorafenib—thyroid cancer	0.00173	0.00295	CcSEcCtD
Adenosine—ADK—Metabolism—NDUFA13—thyroid cancer	0.00172	0.00977	CbGpPWpGaD
Adenosine—Drowsiness—Epirubicin—thyroid cancer	0.00168	0.00288	CcSEcCtD
Adenosine—ADORA2A—G alpha (s) signalling events—CALCA—thyroid cancer	0.00166	0.00944	CbGpPWpGaD
Adenosine—ADA—C-MYB transcription factor network—PTGS2—thyroid cancer	0.00165	0.00937	CbGpPWpGaD
Adenosine—ADK—Metabolism—CHST14—thyroid cancer	0.00162	0.00919	CbGpPWpGaD
Adenosine—ADORA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00162	0.00916	CbGpPWpGaD
Adenosine—Sweating—Epirubicin—thyroid cancer	0.00161	0.00276	CcSEcCtD
Adenosine—Pollakiuria—Doxorubicin—thyroid cancer	0.00161	0.00276	CcSEcCtD
Adenosine—SLC28A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.0016	0.00908	CbGpPWpGaD
Adenosine—SLC28A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.0016	0.00908	CbGpPWpGaD
Adenosine—SLC28A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00157	0.00893	CbGpPWpGaD
Adenosine—Drowsiness—Doxorubicin—thyroid cancer	0.00156	0.00266	CcSEcCtD
Adenosine—Bradycardia—Epirubicin—thyroid cancer	0.00154	0.00263	CcSEcCtD
Adenosine—Hypoaesthesia—Epirubicin—thyroid cancer	0.0015	0.00257	CcSEcCtD
Adenosine—ADORA2B—GPCR downstream signaling—CALCB—thyroid cancer	0.0015	0.00852	CbGpPWpGaD
Adenosine—Sweating—Doxorubicin—thyroid cancer	0.00149	0.00255	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—CCND1—thyroid cancer	0.00149	0.00847	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PRKAR1A—thyroid cancer	0.00146	0.00827	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—PTGS2—thyroid cancer	0.00145	0.0082	CbGpPWpGaD
Adenosine—Bradycardia—Doxorubicin—thyroid cancer	0.00142	0.00243	CcSEcCtD
Adenosine—Tinnitus—Epirubicin—thyroid cancer	0.00141	0.00241	CcSEcCtD
Adenosine—Cardiac disorder—Epirubicin—thyroid cancer	0.0014	0.0024	CcSEcCtD
Adenosine—Flushing—Epirubicin—thyroid cancer	0.0014	0.0024	CcSEcCtD
Adenosine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00139	0.00238	CcSEcCtD
Adenosine—ADA—Metabolism—MINPP1—thyroid cancer	0.00138	0.00781	CbGpPWpGaD
Adenosine—ADORA1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00137	0.00779	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—CALCB—thyroid cancer	0.00136	0.00773	CbGpPWpGaD
Adenosine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00136	0.00233	CcSEcCtD
Adenosine—Arrhythmia—Epirubicin—thyroid cancer	0.00135	0.00231	CcSEcCtD
Adenosine—ADORA1—G alpha (i) signalling events—SST—thyroid cancer	0.00134	0.00762	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—CCND1—thyroid cancer	0.00131	0.00741	CbGpPWpGaD
Adenosine—ADK—Metabolism—HPGD—thyroid cancer	0.00131	0.00741	CbGpPWpGaD
Adenosine—Tinnitus—Doxorubicin—thyroid cancer	0.0013	0.00223	CcSEcCtD
Adenosine—Flushing—Doxorubicin—thyroid cancer	0.0013	0.00222	CcSEcCtD
Adenosine—Cardiac disorder—Doxorubicin—thyroid cancer	0.0013	0.00222	CcSEcCtD
Adenosine—Tension—Epirubicin—thyroid cancer	0.00129	0.00221	CcSEcCtD
Adenosine—Dysgeusia—Epirubicin—thyroid cancer	0.00129	0.0022	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—NRAS—thyroid cancer	0.00129	0.00729	CbGpPWpGaD
Adenosine—Nervousness—Epirubicin—thyroid cancer	0.00128	0.00218	CcSEcCtD
Adenosine—ADORA1—GPCR downstream signaling—CALCB—thyroid cancer	0.00128	0.00724	CbGpPWpGaD
Adenosine—Back pain—Epirubicin—thyroid cancer	0.00127	0.00218	CcSEcCtD
Adenosine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00126	0.00215	CcSEcCtD
Adenosine—ADORA2B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00126	0.00712	CbGpPWpGaD
Adenosine—Arrhythmia—Doxorubicin—thyroid cancer	0.00125	0.00214	CcSEcCtD
Adenosine—Vision blurred—Epirubicin—thyroid cancer	0.00124	0.00212	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—TSHR—thyroid cancer	0.00123	0.00698	CbGpPWpGaD
Adenosine—Agitation—Epirubicin—thyroid cancer	0.00121	0.00207	CcSEcCtD
Adenosine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.0012	0.0068	CbGpPWpGaD
Adenosine—Tension—Doxorubicin—thyroid cancer	0.00119	0.00204	CcSEcCtD
Adenosine—Dysgeusia—Doxorubicin—thyroid cancer	0.00119	0.00204	CcSEcCtD
Adenosine—Nervousness—Doxorubicin—thyroid cancer	0.00118	0.00202	CcSEcCtD
Adenosine—Syncope—Epirubicin—thyroid cancer	0.00118	0.00202	CcSEcCtD
Adenosine—Back pain—Doxorubicin—thyroid cancer	0.00118	0.00201	CcSEcCtD
Adenosine—ADA—Metabolism—NDUFA13—thyroid cancer	0.00117	0.00664	CbGpPWpGaD
Adenosine—Palpitations—Epirubicin—thyroid cancer	0.00116	0.00199	CcSEcCtD
Adenosine—ADORA1—Signaling by GPCR—CALCB—thyroid cancer	0.00116	0.00658	CbGpPWpGaD
Adenosine—Loss of consciousness—Epirubicin—thyroid cancer	0.00116	0.00198	CcSEcCtD
Adenosine—Cough—Epirubicin—thyroid cancer	0.00115	0.00196	CcSEcCtD
Adenosine—Vision blurred—Doxorubicin—thyroid cancer	0.00115	0.00196	CcSEcCtD
Adenosine—Convulsion—Epirubicin—thyroid cancer	0.00114	0.00195	CcSEcCtD
Adenosine—Hypertension—Epirubicin—thyroid cancer	0.00114	0.00194	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—NRAS—thyroid cancer	0.00112	0.00638	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—PRKAR1A—thyroid cancer	0.00112	0.00636	CbGpPWpGaD
Adenosine—Chest pain—Epirubicin—thyroid cancer	0.00112	0.00192	CcSEcCtD
Adenosine—Agitation—Doxorubicin—thyroid cancer	0.00112	0.00191	CcSEcCtD
Adenosine—Anxiety—Epirubicin—thyroid cancer	0.00112	0.00191	CcSEcCtD
Adenosine—Discomfort—Epirubicin—thyroid cancer	0.00111	0.00189	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—KRAS—thyroid cancer	0.00111	0.00627	CbGpPWpGaD
Adenosine—ADA—Metabolism—CHST14—thyroid cancer	0.0011	0.00624	CbGpPWpGaD
Adenosine—Dry mouth—Epirubicin—thyroid cancer	0.0011	0.00187	CcSEcCtD
Adenosine—Syncope—Doxorubicin—thyroid cancer	0.00109	0.00187	CcSEcCtD
Adenosine—Palpitations—Doxorubicin—thyroid cancer	0.00108	0.00184	CcSEcCtD
Adenosine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00107	0.00184	CcSEcCtD
Adenosine—Loss of consciousness—Doxorubicin—thyroid cancer	0.00107	0.00183	CcSEcCtD
Adenosine—ADORA1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00107	0.00606	CbGpPWpGaD
Adenosine—Cough—Doxorubicin—thyroid cancer	0.00106	0.00182	CcSEcCtD
Adenosine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00106	0.00601	CbGpPWpGaD
Adenosine—Shock—Epirubicin—thyroid cancer	0.00106	0.00181	CcSEcCtD
Adenosine—Convulsion—Doxorubicin—thyroid cancer	0.00106	0.0018	CcSEcCtD
Adenosine—Hypertension—Doxorubicin—thyroid cancer	0.00105	0.0018	CcSEcCtD
Adenosine—Tachycardia—Epirubicin—thyroid cancer	0.00105	0.00179	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—PTCH1—thyroid cancer	0.00105	0.00593	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—TSHR—thyroid cancer	0.00105	0.00593	CbGpPWpGaD
Adenosine—ADA—Circadian rythm related genes—PPARG—thyroid cancer	0.00104	0.00593	CbGpPWpGaD
Adenosine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00104	0.00177	CcSEcCtD
Adenosine—Chest pain—Doxorubicin—thyroid cancer	0.00104	0.00177	CcSEcCtD
Adenosine—Anxiety—Doxorubicin—thyroid cancer	0.00103	0.00177	CcSEcCtD
Adenosine—Discomfort—Doxorubicin—thyroid cancer	0.00102	0.00175	CcSEcCtD
Adenosine—Dry mouth—Doxorubicin—thyroid cancer	0.00101	0.00173	CcSEcCtD
Adenosine—SLC28A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00101	0.00571	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDK1—thyroid cancer	0.001	0.0057	CbGpPWpGaD
Adenosine—Hypotension—Epirubicin—thyroid cancer	0.001	0.00172	CcSEcCtD
Adenosine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000994	0.0017	CcSEcCtD
Adenosine—ADORA2A—GPCR downstream signaling—CALCB—thyroid cancer	0.000986	0.00559	CbGpPWpGaD
Adenosine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000979	0.00167	CcSEcCtD
Adenosine—Shock—Doxorubicin—thyroid cancer	0.000978	0.00167	CcSEcCtD
Adenosine—Tachycardia—Doxorubicin—thyroid cancer	0.00097	0.00166	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—KRAS—thyroid cancer	0.000968	0.00549	CbGpPWpGaD
Adenosine—Paraesthesia—Epirubicin—thyroid cancer	0.000964	0.00165	CcSEcCtD
Adenosine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000961	0.00164	CcSEcCtD
Adenosine—Dyspnoea—Epirubicin—thyroid cancer	0.000958	0.00164	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—SST—thyroid cancer	0.000956	0.00543	CbGpPWpGaD
Adenosine—Somnolence—Epirubicin—thyroid cancer	0.000955	0.00163	CcSEcCtD
Adenosine—ADA—C-MYB transcription factor network—HRAS—thyroid cancer	0.00094	0.00533	CbGpPWpGaD
Adenosine—Hypotension—Doxorubicin—thyroid cancer	0.000929	0.00159	CcSEcCtD
Adenosine—ADORA2B—GPCR ligand binding—CALCA—thyroid cancer	0.000921	0.00522	CbGpPWpGaD
Adenosine—Pain—Epirubicin—thyroid cancer	0.000918	0.00157	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000905	0.00155	CcSEcCtD
Adenosine—ADORA2A—Signaling by GPCR—CALCB—thyroid cancer	0.000895	0.00508	CbGpPWpGaD
Adenosine—Paraesthesia—Doxorubicin—thyroid cancer	0.000892	0.00153	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—PTCH1—thyroid cancer	0.000889	0.00504	CbGpPWpGaD
Adenosine—ADA—Metabolism—HPGD—thyroid cancer	0.000887	0.00503	CbGpPWpGaD
Adenosine—Dyspnoea—Doxorubicin—thyroid cancer	0.000886	0.00151	CcSEcCtD
Adenosine—Somnolence—Doxorubicin—thyroid cancer	0.000883	0.00151	CcSEcCtD
Adenosine—Urticaria—Epirubicin—thyroid cancer	0.000853	0.00146	CcSEcCtD
Adenosine—Pain—Doxorubicin—thyroid cancer	0.00085	0.00145	CcSEcCtD
Adenosine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000825	0.00468	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—HRAS—thyroid cancer	0.000823	0.00467	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—SST—thyroid cancer	0.000813	0.00461	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—TSHR—thyroid cancer	0.000807	0.00458	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRG1—thyroid cancer	0.000806	0.00457	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CALCB—thyroid cancer	0.000805	0.00457	CbGpPWpGaD
Adenosine—Hypersensitivity—Epirubicin—thyroid cancer	0.000791	0.00135	CcSEcCtD
Adenosine—Urticaria—Doxorubicin—thyroid cancer	0.000789	0.00135	CcSEcCtD
Adenosine—ADORA1—GPCR ligand binding—CALCA—thyroid cancer	0.000783	0.00444	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—PPARG—thyroid cancer	0.000777	0.00441	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—CDK1—thyroid cancer	0.000772	0.00438	CbGpPWpGaD
Adenosine—Asthenia—Epirubicin—thyroid cancer	0.000771	0.00132	CcSEcCtD
Adenosine—ADORA2B—Signaling Pathways—TRIM33—thyroid cancer	0.000763	0.00433	CbGpPWpGaD
Adenosine—ADK—Metabolism—TPR—thyroid cancer	0.00075	0.00425	CbGpPWpGaD
Adenosine—ADK—Metabolism—PRKAR1A—thyroid cancer	0.000738	0.00418	CbGpPWpGaD
Adenosine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000732	0.00125	CcSEcCtD
Adenosine—ADA—Circadian rythm related genes—PTEN—thyroid cancer	0.000717	0.00407	CbGpPWpGaD
Adenosine—Asthenia—Doxorubicin—thyroid cancer	0.000713	0.00122	CcSEcCtD
Adenosine—Dizziness—Epirubicin—thyroid cancer	0.00071	0.00121	CcSEcCtD
Adenosine—ADORA2B—GPCR downstream signaling—TSHR—thyroid cancer	0.000695	0.00394	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—PTCH1—thyroid cancer	0.000687	0.00389	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CALCB—thyroid cancer	0.000685	0.00388	CbGpPWpGaD
Adenosine—Vomiting—Epirubicin—thyroid cancer	0.000683	0.00117	CcSEcCtD
Adenosine—Rash—Epirubicin—thyroid cancer	0.000677	0.00116	CcSEcCtD
Adenosine—Dermatitis—Epirubicin—thyroid cancer	0.000677	0.00116	CcSEcCtD
Adenosine—Headache—Epirubicin—thyroid cancer	0.000673	0.00115	CcSEcCtD
Adenosine—Dizziness—Doxorubicin—thyroid cancer	0.000657	0.00112	CcSEcCtD
Adenosine—ADORA1—Signaling Pathways—TRIM33—thyroid cancer	0.000649	0.00368	CbGpPWpGaD
Adenosine—Nausea—Epirubicin—thyroid cancer	0.000638	0.00109	CcSEcCtD
Adenosine—Vomiting—Doxorubicin—thyroid cancer	0.000632	0.00108	CcSEcCtD
Adenosine—ADORA2B—Signaling by GPCR—TSHR—thyroid cancer	0.000631	0.00358	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—SST—thyroid cancer	0.000628	0.00356	CbGpPWpGaD
Adenosine—Rash—Doxorubicin—thyroid cancer	0.000627	0.00107	CcSEcCtD
Adenosine—Dermatitis—Doxorubicin—thyroid cancer	0.000626	0.00107	CcSEcCtD
Adenosine—Headache—Doxorubicin—thyroid cancer	0.000623	0.00106	CcSEcCtD
Adenosine—ADORA2B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000621	0.00352	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—NRG1—thyroid cancer	0.00062	0.00352	CbGpPWpGaD
Adenosine—ADORA2A—GPCR ligand binding—CALCA—thyroid cancer	0.000604	0.00343	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—PPARG—thyroid cancer	0.0006	0.0034	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—TSHR—thyroid cancer	0.000591	0.00335	CbGpPWpGaD
Adenosine—Nausea—Doxorubicin—thyroid cancer	0.00059	0.00101	CcSEcCtD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—thyroid cancer	0.000573	0.00325	CbGpPWpGaD
Adenosine—ADK—Metabolism—SLC5A5—thyroid cancer	0.000561	0.00318	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—SST—thyroid cancer	0.000541	0.00307	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—PTCH1—thyroid cancer	0.000537	0.00304	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—TSHR—thyroid cancer	0.000537	0.00304	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—PTEN—thyroid cancer	0.000533	0.00302	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CALCB—thyroid cancer	0.000529	0.003	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000528	0.00299	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—CALCA—thyroid cancer	0.00052	0.00295	CbGpPWpGaD
Adenosine—ADA—Metabolism—TPR—thyroid cancer	0.00051	0.00289	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TCF7L1—thyroid cancer	0.000509	0.00289	CbGpPWpGaD
Adenosine—ADA—Metabolism—PRKAR1A—thyroid cancer	0.000501	0.00284	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TRIM33—thyroid cancer	0.000501	0.00284	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—SST—thyroid cancer	0.000491	0.00278	CbGpPWpGaD
Adenosine—ADA—Circadian rythm related genes—TP53—thyroid cancer	0.000489	0.00277	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—CALCA—thyroid cancer	0.000472	0.00268	CbGpPWpGaD
Adenosine—ADK—Metabolism—RXRA—thyroid cancer	0.000472	0.00268	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—SST—thyroid cancer	0.00046	0.00261	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PTCH1—thyroid cancer	0.000456	0.00259	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—TSHR—thyroid cancer	0.000456	0.00259	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—CALCA—thyroid cancer	0.000442	0.00251	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—BRAF—thyroid cancer	0.000441	0.0025	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TCF7L1—thyroid cancer	0.000433	0.00246	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—CDK1—thyroid cancer	0.000428	0.00243	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—SST—thyroid cancer	0.000417	0.00237	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—TSHR—thyroid cancer	0.000414	0.00235	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—PTEN—thyroid cancer	0.000412	0.00234	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000408	0.00231	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	0.000404	0.00229	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—CALCA—thyroid cancer	0.000402	0.00228	CbGpPWpGaD
Adenosine—ADA—Metabolism—SLC5A5—thyroid cancer	0.000382	0.00216	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TSHR—thyroid cancer	0.000373	0.00211	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000367	0.00208	CbGpPWpGaD
Adenosine—ADORA1—Circadian rythm related genes—TP53—thyroid cancer	0.000364	0.00206	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—CDK1—thyroid cancer	0.000364	0.00206	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	0.00036	0.00204	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—SST—thyroid cancer	0.000355	0.00201	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PTCH1—thyroid cancer	0.000352	0.002	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MEN1—thyroid cancer	0.000351	0.00199	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—CALCA—thyroid cancer	0.000342	0.00194	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TCF7L1—thyroid cancer	0.000334	0.0019	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—SST—thyroid cancer	0.000322	0.00183	CbGpPWpGaD
Adenosine—ADA—Metabolism—RXRA—thyroid cancer	0.000321	0.00182	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TSHR—thyroid cancer	0.000317	0.0018	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTCH1—thyroid cancer	0.000317	0.0018	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000312	0.00177	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—PTEN—thyroid cancer	0.00031	0.00176	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—CALCA—thyroid cancer	0.00031	0.00176	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.00031	0.00176	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MEN1—thyroid cancer	0.000298	0.00169	CbGpPWpGaD
Adenosine—ADK—Metabolism—PPARG—thyroid cancer	0.000298	0.00169	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—SST—thyroid cancer	0.00029	0.00164	CbGpPWpGaD
Adenosine—ADORA2A—Circadian rythm related genes—TP53—thyroid cancer	0.000281	0.00159	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—CDK1—thyroid cancer	0.000281	0.00159	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CALCA—thyroid cancer	0.000279	0.00158	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—NRAS—thyroid cancer	0.000277	0.00157	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTCH1—thyroid cancer	0.00027	0.00153	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	0.000263	0.00149	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CDK1—thyroid cancer	0.000253	0.00143	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—SST—thyroid cancer	0.000247	0.0014	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TSHR—thyroid cancer	0.000245	0.00139	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000241	0.00137	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—KRAS—thyroid cancer	0.000238	0.00135	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CALCA—thyroid cancer	0.000237	0.00135	CbGpPWpGaD
Adenosine—ADK—Metabolism—PTGS2—thyroid cancer	0.000234	0.00133	CbGpPWpGaD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000233	0.00132	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MEN1—thyroid cancer	0.00023	0.00131	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CDK1—thyroid cancer	0.000215	0.00122	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTCH1—thyroid cancer	0.000208	0.00118	CbGpPWpGaD
Adenosine—ADK—Metabolism—PTEN—thyroid cancer	0.000204	0.00116	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NRG1—thyroid cancer	0.000203	0.00115	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—HRAS—thyroid cancer	0.000203	0.00115	CbGpPWpGaD
Adenosine—ADA—Metabolism—PPARG—thyroid cancer	0.000202	0.00115	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SST—thyroid cancer	0.00019	0.00108	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CALCA—thyroid cancer	0.000183	0.00104	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TERT—thyroid cancer	0.000182	0.00103	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—AKT1—thyroid cancer	0.000179	0.00101	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—HIF1A—thyroid cancer	0.000174	0.000988	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NRG1—thyroid cancer	0.000172	0.000978	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CDK1—thyroid cancer	0.000166	0.000941	CbGpPWpGaD
Adenosine—ADA—Metabolism—PTGS2—thyroid cancer	0.000159	0.000903	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TERT—thyroid cancer	0.000155	0.000878	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—NRAS—thyroid cancer	0.000153	0.00087	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—HIF1A—thyroid cancer	0.000148	0.00084	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—BRAF—thyroid cancer	0.000144	0.000818	CbGpPWpGaD
Adenosine—ADA—Metabolism—PTEN—thyroid cancer	0.000139	0.000788	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NRG1—thyroid cancer	0.000133	0.000755	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—KRAS—thyroid cancer	0.000132	0.000749	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—NRAS—thyroid cancer	0.00013	0.00074	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—BRAF—thyroid cancer	0.000123	0.000696	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TERT—thyroid cancer	0.00012	0.000678	CbGpPWpGaD
Adenosine—ADK—Metabolism—AKT1—thyroid cancer	0.000118	0.000668	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HIF1A—thyroid cancer	0.000114	0.000648	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—KRAS—thyroid cancer	0.000112	0.000637	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—HRAS—thyroid cancer	0.000112	0.000637	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—AKT1—thyroid cancer	0.000109	0.000619	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CCND1—thyroid cancer	0.000105	0.000597	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTEN—thyroid cancer	0.000102	0.000576	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—NRAS—thyroid cancer	0.000101	0.000571	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—AKT1—thyroid cancer	9.91e-05	0.000562	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—HRAS—thyroid cancer	9.54e-05	0.000541	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—BRAF—thyroid cancer	9.47e-05	0.000537	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—AKT1—thyroid cancer	9.28e-05	0.000526	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NRAS—thyroid cancer	9.06e-05	0.000514	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CCND1—thyroid cancer	8.95e-05	0.000508	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—KRAS—thyroid cancer	8.67e-05	0.000492	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTEN—thyroid cancer	8.64e-05	0.00049	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—AKT1—thyroid cancer	8.43e-05	0.000478	CbGpPWpGaD
Adenosine—ADA—Metabolism—AKT1—thyroid cancer	8e-05	0.000454	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KRAS—thyroid cancer	7.8e-05	0.000442	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NRAS—thyroid cancer	7.71e-05	0.000437	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—HRAS—thyroid cancer	7.37e-05	0.000418	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—AKT1—thyroid cancer	7.16e-05	0.000406	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TP53—thyroid cancer	6.93e-05	0.000393	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CCND1—thyroid cancer	6.91e-05	0.000392	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTEN—thyroid cancer	6.67e-05	0.000378	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KRAS—thyroid cancer	6.63e-05	0.000376	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—HRAS—thyroid cancer	6.63e-05	0.000376	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—AKT1—thyroid cancer	6.51e-05	0.000369	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NRAS—thyroid cancer	5.95e-05	0.000337	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TP53—thyroid cancer	5.89e-05	0.000334	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—AKT1—thyroid cancer	5.85e-05	0.000332	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—HRAS—thyroid cancer	5.64e-05	0.00032	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KRAS—thyroid cancer	5.12e-05	0.00029	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—AKT1—thyroid cancer	4.98e-05	0.000282	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TP53—thyroid cancer	4.55e-05	0.000258	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HRAS—thyroid cancer	4.35e-05	0.000247	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—AKT1—thyroid cancer	3.84e-05	0.000218	CbGpPWpGaD
